Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (November 2024)
27 slides from Transgene Sa's investor presentation, Nov 7, 2024
Slide 1: Unlocking the Full Potential of the Immune System Against Cancer
Unlocking the Full Potential of the Immune System Against Cancer Corporate Presentation November 7, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Transgene in a Snapshot
Transgene in a Snapshot Click to edit Master title style Lead program TG4050 Additional programs Unique and highly to deliver data and R&I activity to potent and create significant deliver news flow and viral vector based value fuel Transgene’s immunotherapies by 2026 portfolio in the mid term 3
Slide 4: TG4050 – A Novel Individualized Cancer Immunotherapy
TG4050 – A Novel Individualized Cancer Immunotherapy Click to edit Master title style MVA VECTOR BENEFITS THE RIGHT NEOANTIGENS INDICATION Induces broad and specific immune Comprises up to 30 neoantigens Targeting head and neck patients – response – Almost all patients treated selected using NEC’s a
Slide 5: Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors
Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors Click to edit Master Product title style Indication Collaboration Discovery Phase I Phase II INDIVIDUALIZED NEOANTIGEN CANCER VACCINES 24-month median follow-up data on Phase I part Head and neck presented at SITC (Nov. 2024) T
Slide 6: Cancer Therapeutic Vaccines
Cancer Therapeutic Vaccines Focused on delivering the promise of individualized cancer vaccine
Slide 7: myvac® - TG4050 | Combines Unique Know How and Expertise
myvac® - TG4050 | Combines Unique Know How and Expertise Click to edit Master title style MVA viral vector: a powerful Artificial Intelligence to identify platform for vaccine development up to 30 potent neoantigens Strongly immunogenic vector o NEC’s machine learning environment based on o Demonstr
Slide 8: TG4050 | Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy
TG4050 | Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy Click to edit Master title style Need to prevent or delay relapse Phase I/II trial design Approx. 80 patients with locoregionally advanced HPV-negative Clinical situation where checkpoint blockers have failed SCCHN** (NCT: 0418
Slide 9: TG4050 | Generates and/or Expands Tumor Specific T Cells
TG4050 | Generates and/or Expands Tumor Specific T Cells Click to edit Master title style Number of positive responses per patients Head and Neck Cancer trial Despite low mutational burden, De novo responses Amplified responses immunogenic targets could be selected Stable responses* # of neoantigens
Slide 10: TG4050 | Persistent Specific Cellular Response Following Vaccination
TG4050 | Persistent Specific Cellular Response Following Vaccination Click to edit Master title style Patients displayed sustained neoantigen-specific CD8+ responses against multiple selected targets over 7 months Introduction period Boost period Source: G. Le Tourneau et al., “Randomized Phase I Tr
Slide 11: TG4050 | Promising Signals of Clinical Activity in Adjuvant Setting
TG4050 | Promising Signals of Clinical Activity in Adjuvant Setting Click to edit Master title style No related SAEs Head & Neck Cancer Trial Good safety profile 32 patients randomized – September 2024 Median follow-up 6 months 12 months 18 months 24 months 30 months 36 months 42 months of 24.1 mont
Slide 12: TG4050 | Additional Data to be Presented at SITC 2024
TG4050 | Additional Data to be Presented at SITC 2024 Click to edit Master title style one patient • one genome • one vaccine 24.1-month median follow up on Phase I part (32 patients) presented at SITC (Nov. 2024) Signs Excellent of clinical safety Ongoing Phase II part – Last patient to be enrolled
Slide 13: TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer
TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer Click to edit Master title style Randomized Phase II trial in patients with HPV16+ cervical Top line data and anogenital cancer (n=90) incl. cervical, vulvar, vaginal, penile and anal cancers NCT: 03260023 • Primary objec
Slide 14: Oncolytic Viruses
Oncolytic Viruses Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors
Slide 15: Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation
Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Click to edit Master Data Support Intravenous (IV) Route of Administration title style Patented Backbone VVcopTK-RR- vector with multiple Cancer cell death through multiple MOAs competitive ad
Slide 16: BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF
BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF 50/50 collaboration with BioInvent Ongoing Click to edit Phase I/IIa Master title styleTrial Assessing IT* Route of Administration The right virus + payload Ongoing Phase I (NCT04725331) monotherapy and combination w. anti-PD1 VVcopTK-RR- oncolytic armed
Slide 17: TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor
TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor Ongoing Click to edit Phase I Trial Master title style to Assess Systemic Route of Administration Oncolytic armed with IL-12 and anti-CTLA4 Ab • Triggers a powerful antitumor immune response • Restores the immune defenses w
Slide 18: Outlook
Outlook transgene
Slide 19: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Ownership FINANCIAL VISIBILITY As of September 30, 2024 secured until Q4 2025 Enables Transgene to deliver significant milestones including key PoC data for TG4050 and data on all assets 69% Free float 31% • Listed on Euronext Paris • IS
Slide 20: Anticipated Value Creating News
Anticipated Value Creating News Click to edit Master title style TG4050 | Neoantigen vaccine Shared antigens cancer vaccines TG4001: Full analysis ongoing prior to deciding on the Proof of principle best way forward already obtained in Head and Neck cancer (adjuvant) Transgene plans to communicate d
Slide 21: Appendices
Ccremecrane Appendices
Slide 22: New Leadership to Take Transgene to the Next Level
New Leadership to Take Transgene to the Next Level Click to edit Master title style EMMANUELLE DOCHY, ALESSANDRO RIVA, MD MAURIZIO CEPPI, PhD - Chairman & CEO Chief Scientific Officer MD, - VP, Medical Affairs - Chief Medical Officer 30+ years experience LUCIE LARGUIER JAMES WENTWORTH VP, Chief Fina
Slide 23: TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation STANDARD DATA PROCESSING, ROUTINE GENE/EXOME ARTIFICIAL GMP TREATMENT TUMOR BIOPSY SEQUENCING INTELLIGENCE GENE EDITING MANUFACTURING ADMINIS
Slide 24: Transgene, a committed company
Transgene, a committed company Our CSR Click to edit commitments Master title style (Corporate Social Responsibility) 44/100 Vigeo Eiris Transgene's CSR strategy is 85/100 (+20 pts) based on 6 commitments Gaïa EthiFinance Award (+8 pts) To patients 95/100 Equal Employment TOP 5 French companies Inde
Slide 25: Exploration of Tumor TME
Exploration of Tumor TME Challenging population with high prevalence of low/negative TME: tumor micro-environment, TMB: tumor mutational burden, PD-L1 expressors and relatively poor pro-immune infiltrates F:Click to edit fibrotic, Master title style NF: non-fibrotic Arm A: TG4050 single agent Arm B:
Slide 26: Profound Remodelling of Immune Cells Consistent with Anti Tumor Response
Profound Remodelling of Immune Cells Consistent with Anti Tumor Response Suggests that the Click to edit Master Vaccine Effectively Primes the Immune System title style aiveNaive in CD4 in CD4 Naive in CD8b Naive % CD16 in in neg CD8b Memory CD56dim in CD4 NKMemory in CD4 Memory Memory in CD8b Effec
Slide 27: Contact: Lucie Larguier
C O N TA C T Lucie Larguier Chief Financial Officer +33 6 7624 7227 larguier@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr 27